Prognostic value of immune-related genes in laryngeal squamous cell carcinoma

被引:3
作者
Liu, Weixing [1 ]
Zhang, Chunyi [1 ]
Gong, Xin [1 ]
Liao, Wenjing [1 ]
Xu, Jun [1 ]
Zhang, Xiaowen [1 ]
机构
[1] Guangzhou Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, State Key Lab Resp Dis, 151 Yanliangxi Rd, Guangzhou 510120, Guangdong, Peoples R China
关键词
Laryngeal squamous cell carcinoma (LSCC); bioinformatics analyses; immune genes; prognostic model; markers; PATTERN-RECOGNITION RECEPTORS; CANCER; HEAD; SIGNATURE; RECURRENT; IDENTIFICATION; EXPRESSION; FOXP3; ETF1;
D O I
10.21037/tcr-20-2173
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Laryngeal squamous cell carcinoma (LSCC) is a very common cancer in head and neck. A large amount of evidence indicated that immune genes take a non-negligible part in the occurrence and development of LSCC. We aimed to evaluate the prognostic value of the immune-related genes (IRGs) in LSCC. Methods: We analyzed the expression profiles of IRGs and clinical information of patients from The Cancer Genome Atlas (TCGA) dataset, including 114 LSCC and 12 non-tumor tissues. The uncover molecular mechanisms of these survival-associated IRGs (SAIRGs) were explored by the bioinformatics analyses. A novel prognostic model based on IRGs was developed through multivariate Cox regression. Results: Twenty-seven differentially expressed SAIRGs in LSCC patients. Copy number alterations, proteinprotein interaction (PPI) network, transcription factors (TFs) regulate network were used to identify molecular characteristics of these IRGs. We established an IRGs (TLR2, -YCL2, CYSLTR2 and FCGR3B) based prognostic model (IRGPM), which had good performance to predict the prognosis of LSCC (AUC =0.820, P<0.05). Further analysis, we found the IRGPM can reflect the infiltration of several immune cells. Conclusions: IRGs have a potential role in the occurrence and development of LSCC, and the IRGPM can predict the overall survival rate of LSCC.
引用
收藏
页码:6287 / +
页数:17
相关论文
共 52 条
[1]   The "cancer immunogram" [J].
Blank, Christian U. ;
Haanen, John B. ;
Ribas, Antoni ;
Schumacher, Ton N. .
SCIENCE, 2016, 352 (6286) :658-660
[2]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[3]   The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) [J].
Cohen, Ezra E. W. ;
Bell, R. Bryan ;
Bifulco, Carlo B. ;
Burtness, Barbara ;
Gillison, Maura L. ;
Harrington, Kevin J. ;
Quynh-Thu Le ;
Lee, Nancy Y. ;
Leidner, Rom ;
Lewis, Rebecca L. ;
Licitra, Lisa ;
Mehanna, Hisham ;
Mel, Loren K. ;
Raben, Adam ;
Sikora, Andrew G. ;
Uppaluri, Ravindra ;
Whitworth, Fernanda ;
Zandberg, Dan P. ;
Ferris, Robert L. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[4]   Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis [J].
Duaha, Ernest ;
Teegala, Lakshminarayan Reddy ;
Kondeti, Vinay ;
Adapala, Ravi K. ;
Keshamouni, Venkateshwar G. ;
Kanaoka, Yoshihide ;
Austen, K. Frank ;
Thodeti, Charles K. ;
Paruchuri, Sailaja .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (01) :199-204
[5]   Cancer immunotherapy: the beginning of the end of cancer? [J].
Farkona, Sofia ;
Diamandis, Eleftherios P. ;
Blasutig, Ivan M. .
BMC MEDICINE, 2016, 14
[6]   BATF acts as an oncogene in non-small cell lung cancer [J].
Feng, Yu ;
Pan, Liangbin ;
Zhang, Biao ;
Huang, Haitao ;
Ma, Haitao .
ONCOLOGY LETTERS, 2020, 19 (01) :205-210
[7]   Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].
Ferris, R. L. ;
Blumenschein, G., Jr. ;
Fayette, J. ;
Guigay, J. ;
Colevas, A. D. ;
Licitra, L. ;
Harrington, K. ;
Kasper, S. ;
Vokes, E. E. ;
Even, C. ;
Worden, F. ;
Saba, N. F. ;
Iglesias Docampo, L. C. ;
Haddad, R. ;
Rordorf, T. ;
Kiyota, N. ;
Tahara, M. ;
Monga, M. ;
Lynch, M. ;
Geese, W. J. ;
Kopit, J. ;
Shaw, J. W. ;
Gillison, M. L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867
[8]   Postoperative radiotherapy for laryngeal cancer. The prognostic role of programmed death-ligand 1: An immune microenvironment-based cluster analysis [J].
Franz, Leonardo ;
Alessandrini, Lara ;
Ottaviano, Giancarlo ;
di Carlo, Roberto ;
Fasanaro, Elena ;
Ramacciotti, Giulia ;
Contro, Giacomo ;
Marioni, Gino .
PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (09)
[9]   Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma [J].
Ghatalia, Pooja ;
Gordetsky, Jennifer ;
Kuo, Fengshen ;
Dulaimi, Essel ;
Cai, Kathy Q. ;
Deyarajan, Karthik ;
Bae, Sejong ;
Naik, Gurudatta ;
Chan, Timothy A. ;
Uzzo, Robert ;
Hakimi, A. Ari ;
Sonpavde, Guru ;
Plimack, Elizabeth .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[10]   Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial [J].
Gillison, Maura L. ;
Trotti, Andy M. ;
Harris, Jonathan ;
Eisbruch, Avraham ;
Harari, Paul M. ;
Adelstein, David J. ;
Sturgis, Erich M. ;
Burtness, Barbara ;
Ridge, John A. ;
Ringash, Jolie ;
Galvin, James ;
Yao, Min ;
Koyfman, Shlomo A. ;
Blakaj, Dukagjin M. ;
Razaq, Mohammed A. ;
Colevas, A. Dimitrios ;
Beitler, Jonathan J. ;
Jones, Christopher U. ;
Dunlap, Neal E. ;
Seaward, Samantha A. ;
Spencer, Sharon ;
Galloway, Thomas J. ;
Phan, Jack ;
Dignam, James J. ;
Quynh Thu Le .
LANCET, 2019, 393 (10166) :40-50